Immutep has announced topline results from the trial evaluating its eftilagimod alfa in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent and metastatic head and neck squamous cell carcinoma. …
Australian company reports topline results from clinical trial involving MSD's Keytruda
June 28, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Nobody can possibly sustain an argument this is not a price negotiation
August 15, 2025 - - Latest News -
When it comes to PBAC outcomes, it's all in the language, about pricing
August 15, 2025 - - Latest News -
Interim report calls for prevention focus to boost the nation's productivity
August 14, 2025 - - Latest News -
Just because the system involves humans, it does not make it human
August 14, 2025 - - Latest News -
Australian company Mirugen secures backing to process cell technology
August 13, 2025 - - Latest News -
AccessCR’s awards celebrate partnerships between lived experience and science
August 13, 2025 - - Latest News -
Firebrick says Nasodine COVID-19 patent accepted in Europe
August 13, 2025 - - Australian Biotech